Score 0–20: Text explicitly imposes binding manufacturing or production obligations on pharmaceutical companies — mandatory capacity targets, production reservations, local manufacturing requirements, supply prioritisation to EU, or penalties for non-compliance.
Score 21–40: Text subtly increases manufacturing obligations on companies, e.g. reporting on production capacity, conditional support tied to production commitments, or soft incentives for local manufacturing.
Score 41–60: Text is neutral on company manufacturing obligations, or makes procedural changes without clearly tightening or loosening production rules.
Score 61–80: Text subtly reduces manufacturing obligations, e.g. replacing production mandates with voluntary measures, broadening eligibility criteria, or removing capacity reservation requirements.
Score 81–100: Text explicitly removes or weakens manufacturing obligations on pharmaceutical companies, or promotes full commercial freedom on production decisions.